{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:07:35Z","timestamp":1793747255640,"version":"4.6.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277012"],"award-info":[{"award-number":["22277012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20378"],"award-info":[{"award-number":["U22A20378"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejmech.2024.117130","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T06:31:05Z","timestamp":1733639465000},"page":"117130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel diaryl-substituted fused nitrogen heterocycles as tubulin polymerization inhibitors to overcome multidrug resistance in vitro and in vivo"],"prefix":"10.1016","volume":"283","author":[{"given":"Fuhao","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0188-8075","authenticated-orcid":false,"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117130_bib1","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.117130_bib2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/14656566.2017.1316374","article-title":"Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer","volume":"18","author":"Hardin","year":"2017","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.117130_bib3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/13543784.2019.1627326","article-title":"Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds","volume":"28","author":"Tagliamento","year":"2019","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2024.117130_bib4","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/14656566.2024.2369196","article-title":"Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors","volume":"25","author":"Nardin","year":"2024","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.117130_bib5","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ejmech.2024.117130_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics","volume":"73","author":"Siegel","year":"2023","journal-title":"Ca-Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2024.117130_bib7","first-page":"242","article-title":"Recurrence after surgery in patients with NSCLC, Transl","volume":"3","author":"Uramoto","year":"2014","journal-title":"Lung Cancer Res"},{"key":"10.1016\/j.ejmech.2024.117130_bib8","article-title":"Drug resistance in non-small cell lung cancer: a potential for NOTCH targeting?","volume":"8","author":"Iglesias","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2024.117130_bib9","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ejmech.2024.117130_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.117130_bib11","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1517\/14656566.2016.1157581","article-title":"Tubulin inhibitors in non-small cell lung cancer: looking back and forward","volume":"17","author":"Ferrara","year":"2016","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.117130_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev.cellbio.13.1.83","article-title":"Microtubule polymerization dynamics","volume":"13","author":"Desai","year":"1997","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2024.117130_bib13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.117130_bib14","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tredan","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2024.117130_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/BST0330241","article-title":"ABC transporters in the balance: is there a role in multidrug resistance?","volume":"33","author":"Polgar","year":"2005","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejmech.2024.117130_bib16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3892\/ijo.2016.3512","article-title":"Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells","volume":"49","author":"Zhao","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2024.117130_bib17","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-2275(20)31588-1","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"42","author":"Dean","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejmech.2024.117130_bib18","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1021\/acs.jmedchem.2c02115","article-title":"Design, synthesis, and biological evaluation of heterocyclic-fused pyrimidine chemotypes guided by X-ray crystal structure with potential antitumor and anti-multidrug resistance efficacy targeting the colchicine binding site","volume":"66","author":"Tan","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117130_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/biom12121843","article-title":"Recent advances of tubulin inhibitors targeting the colchicine binding site for cancer therapy","volume":"12","author":"Hawash","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2024.117130_bib20","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-11-3376","article-title":"Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer","volume":"18","author":"Nathan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.117130_bib21","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/bjc.2012.165","article-title":"Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial, Brit","volume":"106","author":"Cummings","year":"2012","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejmech.2024.117130_bib22","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1158\/1078-0432.CCR-11-0937","article-title":"Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation","volume":"17","author":"Rischin","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.117130_bib23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/1535-7163.MCT-19-0536","article-title":"An orally available tubulin inhibitor, VERU-111, suppresses triple-negative breast cancer tumor growth and metastasis and bypasses taxane resistance","volume":"19","author":"Deng","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.117130_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112323","article-title":"Discovery of a chiral fluorinated azetidin-2-one as a tubulin polymerisation inhibitor with potent antitumour efficacy","volume":"197","author":"Tang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117130_bib25","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ejmech.2018.04.011","article-title":"Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site","volume":"151","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117130_bib26","doi-asserted-by":"crossref","first-page":"11622","DOI":"10.1021\/acs.jmedchem.4c01122","article-title":"An update on the nitrogen heterocycle compositions and properties of U.S. FDA-approved pharmaceuticals (2013-2023)","volume":"67","author":"Marshall","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117130_bib27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejmech.2019.05.072","article-title":"Design, synthesis, antitumor activities and biological studies of novel diaryl substituted fused heterocycles as dual ligands targeting tubulin and katanin","volume":"178","author":"Gao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117130_bib28","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.febslet.2005.12.060","article-title":"The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research","volume":"580","author":"Gottesman","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2024.117130_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.canlet.2017.05.016","article-title":"BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549\/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe","volume":"402","author":"Bai","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2024.117130_bib30","article-title":"Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance, Drug Resist","volume":"68","author":"Yang","year":"2023","journal-title":"Update"},{"key":"10.1016\/j.ejmech.2024.117130_bib31","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1039\/C5OB00406C","article-title":"Colchicine derivatives with potent anticancer activity and reduced P-glycoprotein induction liability","volume":"13","author":"Singh","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2024.117130_bib32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.chempr.2016.12.005","article-title":"Structural basis of cis- and trans-combretastatin binding to tubulin","volume":"2","author":"Gaspari","year":"2017","journal-title":"Chem"},{"key":"10.1016\/j.ejmech.2024.117130_bib33","doi-asserted-by":"crossref","first-page":"12118","DOI":"10.1021\/acs.jmedchem.4c00878","article-title":"Discovery of novel diaryl-substituted fused heterocycles targeting katanin and tubulin with potent antitumor and antimultidrug resistance efficacy","volume":"67","author":"Jiang","year":"2024","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T18:59:21Z","timestamp":1741287561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424010122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"alternative-id":["S0223523424010122"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117130","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel diaryl-substituted fused nitrogen heterocycles as tubulin polymerization inhibitors to overcome multidrug resistance in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117130"}}